ヒトインスリンの世界市場：ヒトインスリン薬、ヒトインスリン・デリバリーデバイス...市場調査レポートについてご紹介

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 19)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions
2.4.1 Assumptions

3 Executive Summary (Page No. – 27)
3.1 Introduction
3.2 Current Market Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 32)
4.1 Global Market (2015–2020)
4.2 Global Market Size, By Product (2015)
4.3 Global HI Drugs Market Size, By Product Type (2015-2020)
4.4 Global HI Drugs Market Size, By Brand (2014)
4.5 Global HI Delivery Devices Market Size, By Type (2015-2020)
4.6 Global Market Size, By Region (2015-2020)

5 Market Overview (Page No. – 38)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Evolution
5.4 Market Dynamics
5.4.1 Key Market Drivers
5.4.1.1 Growth in the Number of Diabetic Patients
5.4.1.2 Increasing Population Exposure to Key Risk Factors Leading to Diabetes
5.4.1.3 Rising Market Demand for HI Analogs
5.4.1.4 Technological Advancements in HI Delivery Devices
5.4.1.5 Favorable Medical Reimbursement Scenario in Developed Countries
5.4.2 Key Market Restraints
5.4.2.1 Stringent Regulatory Requirements for Product Approval
5.4.3 Key Market Opportunities
5.4.3.1 Emerging Markets
5.4.3.2 Expected Patent Expiry of Key HI Drugs
5.4.4 Key Market Challenge
5.4.4.1 High Product Manufacturing Costs

6 Industry Insights (Page No. – 48)
6.1 Introduction
6.2 Industry Trends
6.2.1 Growing Market Demand for HI Pens
6.2.2 Increasing Market Focus on the Pipeline Development of Novel Human Insulin Therapies
6.3 Pipeline Analysis
6.3.1 By Company
6.3.2 By Clinical Trial Phase
6.3.3 Porter’s Five Force Analysis
6.3.3.1 Threat From New Entrants
6.3.3.2 Threat From Substitutes
6.3.3.3 Bargaining Power of Buyers
6.3.3.4 Bargaining Power of Suppliers
6.3.3.5 Intensity of Competitive Rivalry

7 Global Human Insulin Market, By Product Type (Page No. – 55)
7.1 Introduction
7.2 HI Drugs
7.3 HI Delivery Devices

8 Global Human Insulin Drugs Market, By Type (Page No. – 60)
8.1 Introduction
8.2 Insulin Analogs and Biosimilars
8.2.1 Long-Acting Biosimilars
8.2.2 Rapid-Acting Biosimilars
8.2.3 Premixed Biosimilars
8.3 HI Biologics
8.3.1 Short-Acting Biologics
8.3.2 Intermediate-Acting Biologics
8.3.3 Premixed Biologics

9 Global Human Insulin Drugs Market, By Brand (Page No. – 69)
9.1 Introduction
9.2 HI Analogs and Biosimilars
9.2.1 Lantus
9.2.2 Novorapid and Novolog
9.2.3 Humalog
9.2.4 Other Brands
9.3 HI Biologics
9.3.1 Actrapid, Mixtard, and Insulatard
9.3.2 Humulin
9.3.3 Insuman

10 Global Human Insulin Market, By Delivery Devices (Page No. – 78)
10.1 Introduction
10.2 Syringes
10.3 Pens
10.3.1 Disposable Pens
10.3.2 Reusable Pens
10.4 Pen Needles
10.4.1 Standard Pen Needles
10.4.2 Safety Pen Needles

11 Global Human Insulin Market, By Application (Page No. – 85)
11.1 Introduction
11.2 Type I Diabetes
11.3 Type II Diabetes

12 Human Insulin Market, By Region (Page No. – 90)
12.1 Introduction
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.3 Europe
12.3.1 Germany
12.3.2 France
12.3.3 U.K.
12.3.4 Rest of Europe (RoE)
12.4 Asia-Pacific (APAC)
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Rest of Asia-Pacific (RoAPAC)
12.5 Rest of the World (RoW)

13 Competitive Landscape (Page No. – 107)
13.1 Overview
13.2 Market Share Analysis
13.2.1 HI Drugs Market
13.2.2 HI Delivery Devices Market
13.3 Competitive Scenario
13.4 Recent Developments
13.4.1 Geographical Expansions
13.4.2 Agreements, Collaborations, and Partnerships
13.4.3 New Product Launches
13.4.4 Awareness Programs
13.4.5 Funding & Scholarships
13.4.6 Strategic Acquisitions

14 Company Profiles (Page No. – 119)
14.1 Introduction
14.1.1 Geographic Benchmarking
14.1.2 Strategic Benchmarking
14.1.2.1 Capacity Building
14.1.2.2 Product Development and Commercialization
14.2 B. Braun Melsungen AG
14.2.1 Business Overview
14.2.2 Product Portfolio
14.2.3 Recent Developments
14.3 Becton, Dickinson and Company
14.3.1 Business Overview
14.3.2 Product Portfolio
14.3.3 Recent Developments
14.4 Biocon Limited
14.4.1 Business Overview
14.4.2 Product Portfolio
14.4.3 MnM View
14.5 Biodel Inc.
14.5.1 Business Overview
14.5.2 Product Portfolio
14.5.3 Recent Developments
14.6 ELI Lilly and Company
14.6.1 Business Overview
14.6.2 Product Portfolio
14.6.3 Recent Developments
14.6.4 MnM View
14.7 Julphar (Also Known as Gulf Pharmaceutical Industries)
14.7.1 Business Overview
14.7.2 Product Portfolio
14.7.3 MnM View
14.8 NOVO Nordisk A/S
14.8.1 Business Overview
14.8.2 Product Portfolio
14.8.3 Recent Developments
14.8.4 MnM View
14.9 Sanofi
14.9.1 Business Overview
14.9.2 Product Portfolio
14.9.3 Recent Developments
14.9.4 MnM View
14.10 Wockhardt Limited
14.10.1 Business Overview
14.10.2 Product Portfolio
14.10.3 Recent Developments
14.11 Ypsomed AG
14.11.1 Business Overview
14.11.2 Product Portfolio
14.11.3 Recent Developments

15 Appendix (Page No. – 152)
15.1 Insights of Industry Experts
15.2 Discussion Guide
15.3 Introducing RT: Real-Time Market Intelligence
15.4 Available Customizations
15.5 Related Reports